{"name":"ARCE Therapeutics, Inc.","slug":"arce-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"ARCE Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for patients with significant unmet medical needs. The company's lead candidate, ARD103, is currently in Phase 1 clinical trials.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ARD103","genericName":"ARD103","slug":"ard103","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"ARD103","genericName":"ARD103","slug":"ard103","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxNU0JJdk5ES0NaYjJuTjVlTUNfTkJ4THhIZWZaOUMtaGZUNXQtczlVajlEZGNLWEV3WHNhZXBlLWVRcXRPSEFoTGprU2FMc1BFYTRua01fSFVaS1FyZlE4TmRkT1VOR2U0amFNUEk0QVBmcGo1eWFUVTQ3Mklka0RHbXZiY040b2F3dDVpaW9tZ3hVaWV2Q0NmdEhiS2NNVVdOR29QYTg5U2FrdDBYelh4UVBTNmozWFFPVzNjUlZPOTRTMjBDNTRwUw?oc=5","date":"2025-03-13","type":"earnings","source":"Investing.com","summary":"Earnings call transcript: Akebia Therapeutics Q4 2024 misses EPS forecasts - Investing.com","headline":"Earnings call transcript: Akebia Therapeutics Q4 2024 misses EPS forecasts","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxQMWNVZW5Td01fbjZ1ZjJxRzg3OHJpb1VNQ1ByZWVYa2hTOVF5OEU4Q0RQMWFqN0QxMnV1ZDlHMHFVNnB2NjJJZVRuTENISm90dWZFeWgwb3BpQjdKdmYzZTg5cHRJRGZFRjNaM010d1RXTTNmVXM5a0YwX1lpMGtGUWktcVNFSE1WVUUyWjZqOVBuYm10bThPb3hiZHBodTZoaEs2R0tpU3hnd2lTdklXOWRLRTJBS1FJMFlrWjdn?oc=5","date":"2024-12-31","type":"pipeline","source":"Streetwise Reports","summary":"Analyst Initiates Coverage of Co. With 'Once-in-a-Generation' Drug - Streetwise Reports","headline":"Analyst Initiates Coverage of Co. With 'Once-in-a-Generation' Drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxNUG9JUmhCdkcxLTdZYlZMS1ItMlNHOE9KRG80R0VsVzg0S1hOMFlzSGhvTDlUSWFKcTB3cDBfVlNDMUVZLVlQRnhfUjZNSU5KOGMtTlhOWGM4N0lTU1RHelpnQ1I3cktLcWpiRU0xOG9EZGhJX3psS2ctR1g3NmhQWTN2dW80X2hDQWo0TXZtYmlBbU1HN3JGMWFvQUhfcVNnSWc3UERLLVpCSG8?oc=5","date":"2024-10-09","type":"deal","source":"Streetwise Reports","summary":"H.C. Wainwright & Co. Shares Buy Rating on Biotech Co. - Streetwise Reports","headline":"H.C. Wainwright & Co. Shares Buy Rating on Biotech Co.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxPSGpZLW5hN21yU25obUF4Y0dfU2pLRlRvRWJ2NUhITlg4NXJ6Z0tBdmJZOUI0MW9lVzJ3U0t0TGowdEwycE5WV2NUYjZRYktTU2NEYWhwMEFjU21PRFluWldIOVNhRHN6UjZyakI5MHhodXJIWHpmQXE1cUg0UkhVcnhYVUtPYTBpLU1SdUpYODg2RlNyNV9DRzR4Nkw3LTN6U3pHR0JlVQ?oc=5","date":"2024-09-19","type":"trial","source":"BioWorld News","summary":"Hark, Herald MASH phase II positive but Aligos THRown for a loop - BioWorld News","headline":"Hark, Herald MASH phase II positive but Aligos THRown for a loop","sentiment":"positive"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}